Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
250%(5 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

terminated360%
completed240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

NCT04396366
terminatedphase_2

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT04268823
completedphase_2

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

NCT04072887
completedphase_2

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018
terminatedphase_1

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604

Clinical Trials (5)

Showing 5 of 5 trials
NCT04396366Phase 2

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Terminated
NCT04268823Phase 2

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Terminated
NCT04072887Phase 2

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Completed
NCT02449018Phase 2

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Completed
NCT02190604Phase 1

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5